{
    "clinical_study": {
        "@rank": "115917", 
        "acronym": "(OAT-PIT)", 
        "arm_group": {
            "arm_group_label": "Alcaftadine", 
            "arm_group_type": "Experimental", 
            "description": "subject on any ocular allergy ophthalmic treatment or no treatment will be started on Alcaftadine 0.25%(study drug)- 1 drop each eye daily for 1-2 weeks"
        }, 
        "brief_summary": {
            "textblock": "To study the impact of alcaftadine in patients treated with other opthalmic ocular agents\n      (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting."
        }, 
        "brief_title": "Ocular Allergy Treatment Practical Impact Trial", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Allergic Conjunctivitis", 
            "Rhinoconjunctivitis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Conjunctivitis", 
                "Conjunctivitis, Allergic"
            ]
        }, 
        "detailed_description": {
            "textblock": "To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or\n      no treatment) versus alcaftadine(Lastacaft\u2122)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. patients age 18 and older with a history of seasonal or perennial forms of allergic\n             conjunctivitis and skin test positive reactivity to seasonal aeroallergens\n\n          2. Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.\n\n          3. have allergic ocular symptoms for the past week for which they are either treating\n             with ophthalmic agents or have had no treatment.\n\n          4. Are willing/able to follow instructions from the study investigator and his/her study\n             staff.\n\n          5. Have signed infromed consent approved by Institutional Review Board or Independent\n             Ethics Committee.\n\n             -\n\n        Exclusion Criteria:\n\n          1. Active ocular infection;\n\n          2. History of retinal detachment, diabetic neuropathy, or any progressive retinal\n             disease;\n\n          3. Ocular surgical intervention within three (3) months prior to visit 1 or scheduled\n             during the study.\n\n          4. History of unstable, or uncontrolled disease of any nature.\n\n          5. Pregnancy or lactation;\n\n          6. Have a known hypersensitivity tp LASTACAFT\u2122 (alcaftadine) -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808768", 
            "org_study_id": "ID IIT- 000373"
        }, 
        "intervention": {
            "arm_group_label": "Alcaftadine", 
            "description": "Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.", 
            "intervention_name": "Alcaftadine", 
            "intervention_type": "Drug", 
            "other_name": "Lastacaft"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2013", 
        "location": [
            {
                "contact": {
                    "email": "ejulca1@gmail.com", 
                    "last_name": "Erika Julca, lpn,crc", 
                    "phone": "732-906-1747"
                }, 
                "contact_backup": {
                    "email": "pepejune@gmail.com", 
                    "last_name": "June Pepe, lpn, ccrc", 
                    "phone": "973-912-9817"
                }, 
                "facility": {
                    "address": {
                        "city": "Edison", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08820"
                    }, 
                    "name": "STARx Research Center"
                }, 
                "investigator": [
                    {
                        "last_name": "Jayesh Kanuga, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Ligaya Centeno, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ruby Reyes, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Leonard Bielory, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "DrLBielory@gmail.com", 
                    "last_name": "Leonard Bielory, MD", 
                    "phone": "973-912-9817"
                }, 
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07081"
                    }, 
                    "name": "STARx"
                }, 
                "investigator": {
                    "last_name": "Leonard Bielory, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft\u2122)", 
        "overall_contact": {
            "email": "jkanuga@gmail.com", 
            "last_name": "Jayesh Kanuga, MD", 
            "phone": "732-906-1747"
        }, 
        "overall_contact_backup": {
            "email": "ejulca1@gmail.com", 
            "last_name": "Erika Julca, LPN,CRC", 
            "phone": "732-906-1747"
        }, 
        "overall_official": {
            "affiliation": "Starx Research Center, LLC", 
            "last_name": "Jayesh Kanuga, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Federal Government", 
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Quality of Life- Eye Allergy Patient Impact Questionnaire", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808768"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Starx Research Center, LLC", 
            "investigator_full_name": "Jayesh G. Kanuga, M.D.", 
            "investigator_title": "Medical Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Ocular Surface Disease Index Pollen Count correlation of symptoms", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "source": "Starx Research Center, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Starx Research Center, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}